ResApp Health (ASX:RAP) to raise $5M for European commercialisation
- ResApp Health (RAP) will raise $5 million to accelerate European commercialisation and generate working capital
- ResApp is a health care company that develops digital solutions for the diagnosis and management of respiratory diseases
- In August last year, the company first received European approval for its ResAppDx-EU smartphone app
